EUVIMEDEUVIMED entdecken
Crossref

Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)

Su Chen, Yalu Wei, Qiqi Wang, Yun Li, Fengyan Pei, Wenen Liu, Yunjian Hu, Jiayun Liu, Ying Fei, Shiyang Pan, Zhiyong Liu, Yunsong Yu und 6 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Su Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Antifungal Agents, Fungi, Mycoses. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Key Research and Development Program of China, Merck Sharp & Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the species distribution and antifungal susceptibility profiles of clinical mould isolates from China to olorofim, manogepix, amphotericin B, triazoles and echinocandins.

Methods

Isolates were collected from patients at 10 tertiary hospitals across China between 2019 and 2024. Species identification was performed by sequence analysis. Antifungal susceptibility testing was performed according to the CLSI reference methods. The cyp51A, cyp51B and hmg1 genes from triazole-resistant isolates were amplified to identify mutations associated with resistance.

Results

Aspergillus spp. (92.02%) remained the most prevalent pathogens, followed by Fusarium spp. (4.18%) and Mucorales (1.90%). The proportion of non-A. fumigatus isolates showed an increasing trend. The majority of Aspergillus spp. were susceptible/WT to triazoles (97.52%), with posaconazole showing the highest potency. Among the triazole-resistant Aspergillus isolates, two harboured cyp51A mutations (TR46/Y121F/T289A, G441S) and one carried an hmg1 mutation (V827L). Notably, the novel antifungals olorofim and manogepix were highly potent against most tested moulds, including triazole-resistant Aspergillus isolates. For Fusarium spp., manogepix showed low MECs, whereas olorofim and triazoles showed higher and more species-specific MICs. Both novel agents showed high MIC/MECs against Mucorales isolates, and triazole MIC distributions varied markedly between species.

Conclusions

A. fumigatus sensu stricto remained the predominant pathogen while non-A. fumigatus moulds became increasingly prevalent. Triazole resistance among clinical Aspergillus isolates was uncommon but was associated with cross-resistance and target gene mutations. Novel antifungals olorofim and manogepix demonstrated potent in vitro activity against a broad range of clinical moulds, including triazole-resistant Aspergillus isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsFungiMycosesHumansMicrobial Sensitivity TestsChinaTertiary Care CentersTriazolesDrug Resistance, FungalAmphotericin BEchinocandinsFungal Proteins

Substanzen

Antifungal AgentsTriazolesAmphotericin BEchinocandinsFungal Proteins

Autor:innen und Institutionen

  • Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
  • Research Center for Medical Mycology, Peking University, Beijing, China.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
  • Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Key Research and Development Program of China
  • Merck Sharp & Dohme

Zitieren

APA

Chen, S., Wei, Y., Wang, Q., Li, Y., Pei, F., Liu, W., Hu, Y., Liu, J., Fei, Y., Pan, S., Liu, Z., Yu, Y., Zhao, F., Liu, D., Zhao, J., Wan, Z., Li, R., & Liu, W. (2026). Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag016

Vancouver

Chen S, Wei Y, Wang Q, Li Y, Pei F, Liu W, et al. Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24). Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag016

BibTeX
@article{Chen2026,
  author = {Chen, Su and Wei, Yalu and Wang, Qiqi and Li, Yun and Pei, Fengyan and Liu, Wenen and Hu, Yunjian and Liu, Jiayun and Fei, Ying and Pan, Shiyang and Liu, Zhiyong and Yu, Yunsong and Zhao, Feng and Liu, Dehua and Zhao, Jianhong and Wan, Zhe and Li, Ruoyu and Liu, Wei},
  title = {Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag016}
}
Kostenlos starten →